Atossa Therapeutics Inc (NASDAQ:ATOS) announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No 11,680,036) directed to the company’s enterically encapsulated endoxifen compositions formulated as a suspension.
The clinical-stage biopharmaceutical firm said the patent includes all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets or sprinkles for reconstitution, which are commonly used for pediatric administration.
“Our new patent covering suspension formulations is important as we continue to learn more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density,” Atossa Therapeutics CEO Dr Steven Quay said in a statement.
“Suspension formulations are particularly useful in pediatric applications where drugs are often dosed by weight and delivered via powders or sprinkles mixed with food and dispersible tablets, which are easier for children to ingest compared to tablets,” he added.
Atossa noted that the advantages of suspension formulations may include ease of delivery of low soluble therapeutic agents, increased bioavailability of drug dosage, controlled drug delivery and resistance to degradation.
The company added that it is currently studying (Z)-endoxifen in three Phase 2 studies: one in healthy women with measurable breast density; and two other studies including the EVANGELINE study in women with ER+/HER2- breast cancer.
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer.
Contact Sean at sean@proactiveinvestors.com